Edward Nash
Stock Analyst at Canaccord Genuity
(3.76)
# 786
Out of 5,113 analysts
79
Total ratings
50.7%
Success rate
9.61%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Maintains: Buy | $99 → $100 | $45.85 | +118.10% | 12 | Jan 23, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Hold | $16 → $14 | $13.97 | +0.21% | 8 | Jan 8, 2026 | |
| VERU Veru Inc. | Initiates: Buy | $25 | $2.60 | +861.54% | 1 | Dec 18, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $496.54 | +18.22% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $30.41 | +251.86% | 2 | Nov 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $5.86 | +378.22% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.83 | +192.83% | 3 | Sep 30, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $24.77 | +150.30% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $30.28 | +55.22% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.34 | +571.64% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.25 | +220.00% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $70.69 | +25.90% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $0.99 | +711.61% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.38 | +402.96% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $3.47 | -42.36% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.81 | +22,078.41% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.34 | +402.90% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $24.44 | +235.52% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $23.02 | +108.51% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.83 | +13,357.56% | 1 | Nov 8, 2017 |
Corcept Therapeutics
Jan 23, 2026
Maintains: Buy
Price Target: $99 → $100
Current: $45.85
Upside: +118.10%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Hold
Price Target: $16 → $14
Current: $13.97
Upside: +0.21%
Veru Inc.
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.60
Upside: +861.54%
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $496.54
Upside: +18.22%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $30.41
Upside: +251.86%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $5.86
Upside: +378.22%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.83
Upside: +192.83%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $24.77
Upside: +150.30%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $30.28
Upside: +55.22%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.34
Upside: +571.64%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.25
Upside: +220.00%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $70.69
Upside: +25.90%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $0.99
Upside: +711.61%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.38
Upside: +402.96%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $3.47
Upside: -42.36%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.81
Upside: +22,078.41%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.34
Upside: +402.90%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $24.44
Upside: +235.52%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $23.02
Upside: +108.51%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.83
Upside: +13,357.56%